SDGR News and Press, Schrodinger Inc. From 05/07/24

2024-05-07 12:30:13 ET Summary Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, despite the company progressing drug candidat...

2024-05-02 15:04:30 ET More on Bristol Myers, Schrödinger Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript Schrödinger, Inc. 2024 Q1 - Results - Earnings Call Presentation Bristol Myers Squibb: Tough Times Continue Schrodinger tumbles ...

2024-05-01 20:28:09 ET Schrödinger, Inc. (SDGR) Q1 2024 Earnings Conference Call May 01, 2024, 16:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Jaren Madden - Senior Vice...

2024-05-01 17:12:41 ET More on Schrödinger Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024 Schrödinger, Inc. (SDGR) Q4 2023 Earnings Call Transcript Schrödinger misses top-line and bottom-line estimates; initiates Q2 and reaffirms...

2024-05-01 16:19:40 ET More on Schrödinger Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024 Schrodinger down 15% after hours on soft 2024 guidance Seeking Alpha’s Quant Rating on Schrödinger Read the full article on See...

First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for Initial Phase 1 Data Readouts in Late 2024 or 2025 ...

2024-04-30 17:20:01 ET More on Schrödinger Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024 Schrödinger, Inc. (SDGR) Q4 2023 Earnings Call Transcript Schrodinger down 15% after hours on soft 2024 guidance Schrödinger Non-GA...

2024-04-24 09:19:50 ET More on Moderna Moderna Investors Should Beware Patent-Dispute Fallout Moderna: Considering The Cancer Vaccine Angle Moderna Continues To Build A Pipeline S&P 500 stocks with biggest estimated EPS declines for Q1 Moderna sto...

2024-04-10 12:56:01 ET More on Certara, GoodRx Holdings, etc. GoodRx Holdings: Large TAM Continues To Support Growth Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment Wel...

Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close. The company will host a conference call...